A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Head-and-neck Squamous-cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Ficlatuzumab
BIOLOGICAL: Cetuximab
OTHER: Placebo

Sponsor

AVEO Pharmaceuticals, Inc.